Compare Incyte Corporation (INCY) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Kohl's Corporation — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Kohl's Corporation trades at $18.06 (market cap $1.99B). The key difference: Incyte Corporation is far larger — about 11.6× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.85% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | KSS | |
|---|---|---|
Market Cap | $23.11B | $1.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $24.71 |
52-Week Low | $67.38 | $10.42 |
Enterprise Value | $19.13B | $8.10B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Kohl's (KSS) trades at $18.12, up 4.74% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $16.75. The stock shows low valuation multiples with a P/E of 7.38 and P/S of 0.13, while recent earnings have beaten expectations. Revenue has declined from $19.4B in 2022 to $16.2B in 2025, but net income improved to $109M. The company is focusing on proprietary brands and operational improvements under new leadership.
The outlook suggests a turnaround opportunity with attractive valuations and recent operational progress, but risks include persistent revenue declines and competitive pressures. Investor sentiment is mixed, with analysts divided between buy and hold ratings. Upside depends on successful execution of the company's revitalization strategy amid a challenging retail environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
